Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of
molecular alterations, and as such, long-term disease control requires multiple therapeutic …

Aberrant FLT3 receptor signaling is common in acute myeloid leukemia (AML) and has
important implications for the biology and clinical management of the disease. Patients with …

FMS-related tyrosine kinase 3 (FLT3) mutations, present in about 25%-30% of acute myeloid
leukemia (AML) patients, constitute one of the most frequently detected mutations in these …

Acute myeloid leukemia (AML) is a myeloid malignancy that is characterized by the
accumulation of leukemic blast cells, which originate from hematopoietic stem cells that …

Background Acute myeloid leukemia (AML) evolves from neoplastic transformation of stem
cell disease termed “leukemia stem cells”(LSCs). An unsatisfactory response to AML therapy …

As CAR T-cell therapy has advanced in B-cell acute lymphoblastic leukemia, research is
now underway to develop similar therapies for other lymphoid and myeloid malignancies for …

Background Fms-like tyrosine kinase 3 (FLT3) expression and mutation have been
considered a poor prognostic factor in acute myeloid leukemia (AML). FLT3-ITD mutation is …

Objectives Midostaurin, a multikinase and FLT3 inhibitor, is the first non‐chemotherapy
agent approved and widely adopted for the treatment of FLT3‐ITD acute myeloid leukemia …

Background: The outcome of acute myeloid leukemia (AML) is influenced by ethnicity,
geographic variations, and the patient's molecular profile. We aimed to explore the mutation …

Objective The objective of this study is to investigate how lymphoid progenitor mechanisms
contribute to the leukemogenesis in Acute Lymphoblastic Leukemia. Background Acute …